Researchers at Cedars‑Sinai identified the enzyme UBE2N as a natural defender against worsening fatty liver disease, offering a potential new target to prevent progression to MASH.
Researchers at Cedars‑Sinai identified the enzyme UBE2N as a natural defender against worsening fatty liver disease, offering a potential new target to prevent progression to MASH.